12 February 2021: We have reviewed the evidence on the effects of systemic anticancer treatment on risk of severe illness or death in patients with cancer and COVID-19 and made new recommendations. We added vaccination status to the first bullet point of recommendation 3.3 and emphasised the importance of reaching a shared decision in recommendation 4.5
9 November 2020: We amended recommendation 4.3 because deferring treatments that prevent long-term complications is no longer recommended. We added subcutaneous medicines to the medicines that can be provided by home delivery.
27 April 2020: We updated the table on interim treatment options in line with new advice from NHS England and NHS Improvement. Check the table for updates.
9 April 2020: We amended recommendation 4.3 to include NHS England interim treatment options as an option. We added 4 recommendations on these interim treatment regimens and linked to the table on interim treatment regimens on the resources tab.
3 April 2020: We amended table 1 in line with new advice from NHS England on prioritising treatments.
Minor changes since publication
26 May 2020: We aligned recommendation 1.4 with current government advice on social distancing and recommendation 2.5 with current government advice on managing exposed staff and patients in health and social care settings.